These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 35377656)

  • 1. Brij Niosomes as Carriers for Sustained Drug Delivery─A Fluorescence-Based Approach to Probe the Niosomal Microenvironment.
    Sarkar S; De S
    Langmuir; 2022 Apr; 38(15):4521-4537. PubMed ID: 35377656
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tailoring Niosomes- Implications for Controlled Cargo Release and Function as Nanoreactors.
    Sarkar S; De S
    J Fluoresc; 2022 May; 32(3):907-920. PubMed ID: 35102460
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro study of polyoxyethylene alkyl ether niosomes for delivery of insulin.
    Pardakhty A; Varshosaz J; Rouholamini A
    Int J Pharm; 2007 Jan; 328(2):130-41. PubMed ID: 16997517
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hydroxychloroquine niosomes: a new trend in topical management of oral lichen planus.
    Bendas ER; Abdullah H; El-Komy MH; Kassem MA
    Int J Pharm; 2013 Dec; 458(2):287-95. PubMed ID: 24184035
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development and characterization of mixed niosomes for oral delivery using candesartan cilexetil as a model poorly water-soluble drug.
    Sezgin-Bayindir Z; Antep MN; Yuksel N
    AAPS PharmSciTech; 2015 Feb; 16(1):108-17. PubMed ID: 25204859
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Formulation and Evaluation of Niosomal in situ Nasal Gel of a Serotonin Receptor Agonist, Buspirone Hydrochloride for the Brain Delivery via Intranasal Route.
    Mathure D; Madan JR; Gujar KN; Tupsamundre A; Ranpise HA; Dua K
    Pharm Nanotechnol; 2018; 6(1):69-78. PubMed ID: 29380709
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro Characterization and Release Studies of Combined Nonionic Surfactant-Based Vesicles for the Prolonged Delivery of an Immunosuppressant Model Drug.
    Rasul A; Imran Khan M; Ur Rehman M; Abbas G; Aslam N; Ahmad S; Abbas K; Akhtar Shah P; Iqbal M; Ahmed Al Subari AM; Shaheer T; Shah S
    Int J Nanomedicine; 2020; 15():7937-7949. PubMed ID: 33116510
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Niosomes for oral delivery of nateglinide: in situ-in vivo correlation.
    Sultan AA; El-Gizawy SA; Osman MA; El Maghraby GM
    J Liposome Res; 2018 Sep; 28(3):209-217. PubMed ID: 28618876
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Caffeine-loaded niosomes: characterization and in vitro release studies.
    Khazaeli P; Pardakhty A; Shoorabi H
    Drug Deliv; 2007 Oct; 14(7):447-52. PubMed ID: 17994362
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development and evaluation of nanosized niosomal dispersion for oral delivery of Ganciclovir.
    Akhter S; Kushwaha S; Warsi MH; Anwar M; Ahmad MZ; Ahmad I; Talegaonkar S; Khan ZI; Khar RK; Ahmad FJ
    Drug Dev Ind Pharm; 2012 Jan; 38(1):84-92. PubMed ID: 21726136
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sorbitan ester niosomes for topical delivery of rofecoxib.
    Das MK; Palei NN
    Indian J Exp Biol; 2011 Jun; 49(6):438-45. PubMed ID: 21702223
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro characterisation of Span 65 niosomal formulations containing proteins.
    Haj-Ahmad RR; Elkordy AA; Chaw CS
    Curr Drug Deliv; 2015; 12(5):628-39. PubMed ID: 25963305
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Non-ionic surfactant vesicles as a carrier system for dermal delivery of (+)-Catechin and their antioxidant effects.
    Li D; Martini N; Liu M; Falconer JR; Locke M; Wu Z; Wen J
    J Drug Target; 2021 Mar; 29(3):310-322. PubMed ID: 33044095
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recent advances in non-ionic surfactant vesicles (niosomes): Fabrication, characterization, pharmaceutical and cosmetic applications.
    Chen S; Hanning S; Falconer J; Locke M; Wen J
    Eur J Pharm Biopharm; 2019 Nov; 144():18-39. PubMed ID: 31446046
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Impact of Surfactant Composition and Surface Charge of Niosomes on the Oral Absorption of Repaglinide as a BCS II Model Drug.
    Yaghoobian M; Haeri A; Bolourchian N; Shahhosseni S; Dadashzadeh S
    Int J Nanomedicine; 2020; 15():8767-8781. PubMed ID: 33204087
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhancement of lomefloxacin Hcl ocular efficacy via niosomal encapsulation: in vitro characterization and in vivo evaluation.
    Khalil RM; Abdelbary GA; Basha M; Awad GEA; El-Hashemy HA
    J Liposome Res; 2017 Dec; 27(4):312-323. PubMed ID: 27241274
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current Advances in Specialised Niosomal Drug Delivery: Manufacture, Characterization and Drug Delivery Applications.
    Witika BA; Bassey KE; Demana PH; Siwe-Noundou X; Poka MS
    Int J Mol Sci; 2022 Aug; 23(17):. PubMed ID: 36077066
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design and in vitro characterization of small unilamellar niosomes as ophthalmic carrier of dorzolamide hydrochloride.
    Hasan AA
    Pharm Dev Technol; 2014 Sep; 19(6):748-54. PubMed ID: 23964893
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of niosomes prepared with various nonionic surfactants for paclitaxel oral delivery.
    Bayindir ZS; Yuksel N
    J Pharm Sci; 2010 Apr; 99(4):2049-60. PubMed ID: 19780133
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alkyl glucopyranoside-based niosomes containing methotrexate for pharmaceutical applications: evaluation of physico-chemical and biological properties.
    Muzzalupo R; Tavano L; La Mesa C
    Int J Pharm; 2013 Dec; 458(1):224-9. PubMed ID: 24060370
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.